HorizonBull Posted - 22 hours ago

$VNDA nice solid close

johnle66 Posted - 1 day ago

$VNDA

Uid10Tengo Posted - 1 day ago

$VNDA To be honest, I started trading this stock back in late October. It has been pretty lack luster... not really impressed.

10sense Posted - 1 day ago

$VNDA I bought a new batch today let's go

Basti0609 Posted - 2 days ago

$VNDA im in

HorizonBull Posted - 2 days ago

$VNDA so cheap and undervalued

Thestocktraderhubzee Posted - 2 days ago

$VNDA HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

BioRich Posted - 2 days ago

$ESPR $TEM $LPCN $VNDA $SRPT due for big days! Let's go!

HorizonBull Posted - 2 days ago

$VNDA will not sell a single share under 10

johnle66 Posted - 4 days ago

$VNDA https://www.marketwatch.com/story/vanda-pharmaceuticals-gets-fda-orphan-drug-designation-for-cancer-treatment-b3b6e61c?mod=mw_quote_news

jacckkmm Posted - 4 days ago

$VNDA

johnle66 Posted - 4 days ago

$VNDA 10,000 more shares purchased I am averaging up, but I will keep going. 100% confident

HorizonBull Posted - 5 days ago

$VNDA loaded more

Rustic1752 Posted - 5 days ago

$VNDA Black Rock owns 14 % of company and Vanguard owns 6%. Just a matter of time when it pops up​ with new FDA approval today

HFlier Posted - 5 days ago

$VNDA Hey VNDA do me a favor and announce the buy-out today. I have some $6.00 calls expiring today lol.

Mrkeli Posted - 5 days ago

$VNDA good news today, i belive they have more news in upcoming days

Stoveman2 Posted - 5 days ago

$Gv bottomed again, round 2? $ptix Uptrending $vnda had news

HFlier Posted - 5 days ago

$VNDA No volume and no interest.

skyrockets_Inc Posted - 5 days ago

$VNDA -VPO-227, a CFTR inhibitor for the treatment of cholera, has received approval to proceed in a Phase I study in Bangladesh, a country where the treatment of cholera remains a significant and unmet need. Vanda plans to initiate this study by the end of 2024. The Phase I clinical study for VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), an inherited peripheral neuropathy for which there is no available treatment, expects to enroll the patient by the end of 2024 The Phase I clinical study for VTR-297 for the treatment of onychomycosis, a fungal infection of the nail, was initiated in April 2024. The study is fully enrolled, and results are expected by the end of 2024.

skyrockets_Inc Posted - 5 days ago

$VNDA So much to get done by end of 2024! I think next update will be Phase 1 results for VTR-297 (last one on next post) -Vanda expects to initiate a Phase III program for milsaperidone for major depressive disorder (MDD) by the end of 2024. -Iloperidone long acting injectable (LAI): Vanda expects to initiate a Phase III program for the LAI formulation of Fanapt® in the fourth quarter of 2024. -Vanda expects Investigational New Drug (IND) applications for PONVORY® in the treatments of psoriasis and ulcerative colitis to be completed in the fourth quarter of 2024. -Motion Sickness NDA: Vanda expects to submit an NDA for tradipitant for the treatment of motion sickness to the FDA in the fourth quarter of 2024. -Vanda plans to initiate a clinical trial to study tradipitant in the prevention of vomiting induced by a GLP-1 analog (semaglutide) in the fourth quarter of 2024

skyrockets_Inc Posted - 5 days ago

$VNDA I think we are about to get a string of PR's . Lots of things are supposed to be updated before Q4 end

Moises_Christensen Posted - 5 days ago

$VNDA $ELDN $INZY 🔥 MYNZ 🔥 +58% yesterday n today +21% - Rumor on FDA submission soon, this time I'm believing, as TMO (Thermo Fisher) ($202.8B market cap, $42.86B 2023 revenue) backing with Vanguard and BlackRock, and DGX (Quest Diagnostics) ($17.3B market cap, $9.25B revenue), it's definitely will move upside as analysts PT updated to $120 and $440 it's insane 3000% and 12000% 🔥🚀🚀🚀

MDHOOD Posted - 5 days ago

$VNDA News is out! Orphan drug designation!

Scanners_Free Posted - 5 days ago

$VNDA NNNNNNNEWSSSS

BadDecisionz Posted - 5 days ago

$VNDA 5) Obviously this isn't recent news but give us $10 and i'll be pleased.

BadDecisionz Posted - 5 days ago

$VNDA 4) The rejection followed an unsuccessful Phase 3 clinical trial, where tradipitant didn’t reach its primary endpoint and performed no better than a placebo. We urge Vanda shareholders to express their views on this proposal to the independent directors of the Vanda Board of Directors. We stand ready to work immediately with Vanda’s Board and management team to reach an agreement that would provide a compelling premium and certain cash value today for all Vanda shareholders.”

BadDecisionz Posted - 5 days ago

$VNDA 3) Unfortunately, instead of reviewing and responding to our proposal, Vanda held a Board meeting to update its bylaws to further entrench the Board, which included the addition of multiple procedural obstacles in the way of nominating directors, unilaterally adding a whole new layer of arbitrary rules to the detriment of Vanda shareholders, all while failing to disclose the $8 per share cash offer that, in our view, clearly motivated the bylaw amendments in the first place. Most notably, these changes would apply ahead of Vanda’s forthcoming annual meeting. Shortly thereafter, Vanda rejected our proposal. In short, it is clear that Vanda’s Board is not acting in the best interests of shareholders. Even more concerning is Vanda’s failure to receive FDA clearance for tradipitant, whose prospects had been prominently cited in June by Vanda for its rejection of our initial offer.

BadDecisionz Posted - 5 days ago

$VNDA 2) Despite the significant value and highly attractive premium of our proposal, Vanda’s Board and management team have refused to engage with us to discuss its merits and instead, have continued to prioritize their own interests and self-preservation with egregious actions that blatantly disenfranchise Vanda shareholders. When Vanda requested an additional two weeks to review our proposal, we gave them the extension as requested, underscoring our continued flexibility and willingness to collaborate in creating the best outcome for Vanda shareholders.

BadDecisionz Posted - 5 days ago

$VNDA 1) On October 3, 2024, despite the active proposal from Cycle, Vanda’s Board amended and restated its bylaws, which included further entrenching modifications related to both annual and special stockholder meetings and the nomination of directors, as well as the Vanda Board’s ability to postpone, reschedule or cancel any such meetings and restrict stockholder business or director nominees that can be made at such meetings. Two business days later, on October 7, the Vanda board rejected Cycle’s proposal. Cycle today issued the following statement: “We are confident that our $8.00 per share, all-cash proposal maximizes value and would deliver immediate, compelling and certain cash value for Vanda shareholders.

buyhiselow Posted - 5 days ago

$VNDA I got $6 calls for next June so we will see if this can run.